Clinical trials: Cutaneous Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma (HNSCC)
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
The purpose of this study is to determine the false negative rate (FNR) associated with Lymphoseek-identified sentinel lymph nodes (SLNs) relative to the pathological status of non-sentinel lymph nodes in elective neck dissection…
- Trial name
- NCT00911326
- Testing
- Lymphoseek
- Where
- 13 sites in United States
- Volunteers
- 101 people
- Sponsor
- Navidea Biopharmaceuticals
Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal, Colorectal Cancer, Squamous Cell Carcinoma of the Lung
- Trial name
- NCT04429542
- Testing
- BCA101, Pembrolizumab
- Where
- 21 sites in United States, Australia and 1 more
- Volunteers
- 473 people
- Sponsor
- Bicara Therapeutics
Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer
A Study of VET3-TGI in Patients With Solid Tumors
VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by…
- Conditions
- Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer
- Trial name
- STEALTH-001 (NCT06444815)
- Testing
- VET3-TGI, Atezolizumab
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- KaliVir Immunotherapeutics
Actinic Keratosis, Bowen's Disease
Clinical Study Assessment of SR-T100 Topical Gel Against Actinic Keratosis
To evaluate the efficacy of SR-T100 gel by observing the lesion size (length x width x height) of human cutaneous squamous cell carcinoma in situ (Actinic Keratosis and Bowen's Disease) reduced at least 75%.
- Trial name
- AK (NCT02085395)
- Testing
- SR-T100 ® Gel
- Where
- Taiwan
- Volunteers
- 27 people
- Sponsor
- G&E Herbal Biotechnology Co., LTD
Cutaneous Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer
To estimate the clinical benefit of cemiplimab monotherapy versus cemiplimab in combination with RP1 for patients with locally advanced or metastatic CSCC, as assessed by overall response rate (ORR) and complete response rate…
- Conditions
- Cutaneous Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma
- Trial name
- CERPASS (NCT04050436)
- Testing
- Cemiplimab, RP1
- Where
- 56 sites in United States, Australia and 8 more
- Volunteers
- 231 people
- Sponsor
- Replimune, Inc.
Cutaneous Squamous Cell Carcinoma
A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma
This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced Cutaneous Squamous Cell Carcinoma.
- Trial name
- NCT05888844
- Testing
- INCB099280
- Where
- 77 sites in Australia, Brazil and 13 more
- Volunteers
- 63 people
- Sponsor
- Incyte Corporation
Carcinoma, Squamous Cell, Skin Neoplasms
A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)
This is a two-part (Phase 2/Phase 3) study of intismeran autogene, an individualized neoantigen therapy (INT), plus pembrolizumab in participants with locally resectable advanced cutaneous squamous cell carcinoma (LA cSCC).
- Trial name
- INTerpath-007 (NCT06295809)
- Testing
- Pembrolizumab, Intismeran autogene, Surgery
- Where
- 106 sites in United States, Argentina and 18 more
- Volunteers
- 46 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Solid Tumor
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
This is a study to evaluate the safety and potential anti-tumor activity of an investigational drug called ARV-6723, in participants with advanced solid tumors.
- Trial name
- NCT07749586
- Testing
- ARV-6723, Pembrolizumab, SOC
- Where
- 4 sites in United States
- Volunteers
- 499 people
- Sponsor
- Arvinas Inc.
Facial isSCC
Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Adults With Facial isSCC
Open label, dose escalation to evaluate safety.
- Trial name
- isSCC (NCT05421013)
- Testing
- STP705
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Sirnaomics
Solid Tumors, Mycosis Fungoides
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
This is a multicenter, open-label, phase 1 study conducted to test intratumoral injections of TTI-621 in subjects that have relapsed and refractory percutaneously accessible solid tumors or mycosis fungoides.
- Conditions
- Solid Tumors, Mycosis Fungoides, Melanoma, Merkel-cell Carcinoma
- Trial name
- NCT02890368
- Testing
- TTI-621 Monotherapy, TTI-621 + PD-1/PD-L1 Inhibitor, TTI-621 + pegylated interferon-α2a
- Where
- 7 sites in United States
- Volunteers
- 56 people
- Sponsor
- Pfizer
Advanced Solid Tumor
A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors
This is a first-in-human, Phase 1/2 open-label, multicenter, dose escalation, safety, pharmacodynamic, and PK study of CDK-002 in subjects with advanced/metastatic, recurrent, injectable solid tumors, whose disease has progressed…
- Trial name
- NCT04592484
- Testing
- CDK-002
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 27 people
- Sponsor
- Codiak BioSciences
Recurrent Squamous Cell Carcinoma
Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma
This is a multi-center clinical study enrolling up to 86 participants. The primary objectives are to determine the objective response rate (ORR) established by the confirmed best overall response (BOR) following intratumoral…
- Trial name
- NCT05323253
- Testing
- DaRT seeds
- Where
- 28 sites in United States, Canada and 1 more
- Volunteers
- 86 people
- Sponsor
- Alpha Tau Medical LTD.
Cancer, Melanoma
Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors
ONCR-177-101 is a phase 1, open-label, multi-center, dose escalation and expansion study of ONCR-177, an oncolytic Herpes Simplex Virus for intratumoral injection, alone and in combination with PD-1 blockade in adult subjects…
- Conditions
- Cancer, Melanoma, Solid Tumor, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT04348916
- Testing
- ONCR-177, pembrolizumab
- Where
- 11 sites in United States, Canada
- Volunteers
- 66 people
- Sponsor
- Oncorus, Inc.
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Skin Cancer, Mucosal Neoplasm of Oral Cavity
Retreatment With Intratumoral Diffusing Alpha Radiation Emitters
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
- Conditions
- Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
- Trial name
- NCT04540588
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Israel
- Volunteers
- 2 people
- Sponsor
- Alpha Tau Medical LTD.
Locally Advanced Cutaneous Squamous Cell Carcinoma
L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma
Open-label, single-arm, multicenter study in patients with locally advanced, histologically confirmed Cutaneous Squamous Cell Carcinoma (LacSCC) amenable to intratumoral injection, who have progressed on or are intolerant to…
- Trial name
- NCT07228442
- Testing
- L19IL2/L19TNF
- Where
- 19 sites in United States, Germany and 3 more
- Volunteers
- 92 people
- Sponsor
- Philogen S.p.A.
Squamous Cell Cancer, Squamous Cell Carcinoma
Topical Ascorbic Acid for Treatment of Squamous Cell Skin Cancer
Randomized comparative trial of a 30% solution of ascorbic acid in 95% dimethylsulfoxide applied topically twice a day for 8 weeks vs 5% imiquimod cream in the treatment of biopsy proven squamous cell carcinomas of the skin in…
- Conditions
- Squamous Cell Cancer, Squamous Cell Carcinoma, Skin Cancer, Non-melanoma Skin Cancer
- Trial name
- NCT05932511
- Testing
- 30% ascorbic acid in DMSO
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Center for Biomedical Research, Inc.